Aldeyra Therapeutics (ALDX) Assets Average (2014 - 2026)

Aldeyra Therapeutics' Assets Average history runs 13 years deep, the most recent figure standing at $69.3 million for Q1 2026.

• Quarterly Assets Average fell 29.96% year-over-year to $69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.3 million (down 29.96% YoY) and the FY2025 annual result came in at $88.3 million, down 30.15% from the prior year.
• Assets Average was $69.3 million for Q1 2026 at Aldeyra Therapeutics, down from $74.9 million in the prior quarter.
• Across five years, Assets Average topped out at $227.9 million in Q1 2022 and bottomed at $69.3 million in Q1 2026.
• A 5-year average of $140.1 million and a median of $144.8 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average jumped 97.62% — and 2025, when it sank 33.36%.
• Aldeyra Therapeutics' Assets Average stood at $185.5 million in 2022, then dropped by 20.32% to $147.8 million in 2023, then declined by 24.93% to $111.0 million in 2024, then slumped by 32.47% to $74.9 million in 2025, then dropped by 7.55% to $69.3 million in 2026.
• Business Quant data shows ALDX's Assets Average at $69.3 million in Q1 2026, $74.9 million in Q4 2025, and $81.4 million in Q3 2025.